Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 16

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 16
---
 with our HexaBody technology platform, bispecific antibodies created with our DuoBody technology platform and ADCs created with our ADC technology platforms. We are also collaborating with our partners to generate additional new antibody-based product concepts. A number of the preclinical programs are conducted in cooperation with our collaboration partners.

Programs Incorporating Genmab’s Innovation and Technology 1

In addition to Genmab’s own pipeline of investigational medicines and preclinical pipeline candidates, our innovations and proprietary technology platforms are applied in the pipelines of global pharmaceutical and biotechnology companies. These companies are running clinical development programs with antibodies created by Genmab or created using Genmab’s proprietary DuoBody bispecific antibody technology platform.

The information in this section includes those therapies that have been approved by regulatory agencies in certain territories. Under the agreements for these medicines Genmab is entitled to certain potential milestones and royalties.

| Genmab A/S            
 Carl Jacobsens Vej 30 
 2500 Valby, Denmark   |     | Tel: +45 7020 2728 
 www.genmab.com     |     | Company Announcement no. 40 
 Page 11/44                  
 CVR no. 2102 3884           |

#### Interim Report for the First Half of 2025

#### Approved Medicines
| Approved Product                     |     | Discovered and/or Developed & Marketed By                                                 |     | Disease Indication(s)2                                                       |
| DARZALEX                             
 (daratumumab)/DARZALEXFASPRO         
 (daratumumab and hyaluronidase-fihj) |     | J&J (Royalties to Genmab on global net sales)                                             |     | Multiple myeloma                                                             
 Light-chain (AL) Amyloidosis                                                 |
| Kesimpta                             
 (ofatumumab)                         |     | Novartis (Royalties to Genmab on global net sales)                                        |     | Relapsing multiple sclerosis (RMS)                                           |
| TEPEZZA                              
 (teprotumumab-trbw)                  |     | Amgen Inc. (Amgen) (under sublicense from Roche, royalties to Genmab on global net sales) |     | Thyroid Eye Disease (TED)                                                    |
| RYBREVANT                            
 (amivantamab/amivantamab-vmjw)       |     | J&J (Royalties to Genmab on global net sales)                                             |